Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Captor Therapeutics Spolka Akcyjna (CTX.WA)
Wroclaw, SL, PL
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. Its products in various stages of development include CT-03, which has completed the Phase 1 clinical trials for the treatment of non-small cell lung cancer, triple-negative breast cancer, as well as cancers of the blood, lymphatic system, and bone marrow; and CT-01, which also completed the Phase 1 clinical trials for the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor. The company was incorporated in 2015 and is headquartered in Wroclaw, Poland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.63% | +0.26% | -1.02% | -4.88% | +18.54% | +4.00% | +144.51% | -51.55% | -53.85% | -49.36% | -49.36% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%-70.6% Q1'26: -87.4% (vs Q1'25)
-
EPS growth Medical - Pharmaceuticals: +20.2%+7.8% Q1'26: -7.7% (vs Q1'25)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-1,042.2% Q1'26: -3,859.5% (vs Q1'25)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-1,141.8% Q1'26: -3,439.3% (vs Q1'25)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'26: +1,709.2% (vs Q1'25)
-
Share dilution Medical - Pharmaceuticals: +0.0%+18.4% Q1'26: +0.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.07× Q1'26: -0.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
3.99M
est: 3.90M (+2.2%)
|
9.16M
est: 9.20M (-0.5%)
|
13.20M
est: 18.64M (-29.2%)
|
15.83M
est: 22.00M (-28.1%)
|
4.66M
est: 6.18M (-24.5%)
|
39.10M
27.39M – 50.81M
+533.2% YoY
|
72.00M
14.85M – 129.15M
+84.1% YoY
|
43.00M
30.12M – 55.88M
-40.3% YoY
|
| EBITDA |
-24.41M
est: -2.34M (-943.2%)
|
-28.22M
est: -5.52M (-411.3%)
|
-64.76M
est: -18.64M (-247.4%)
|
-32.93M
est: -22.00M (-49.7%)
|
-48.84M
est: -6.18M (-690.9%)
|
-39.10M
-50.81M – -27.39M
-533.2% YoY
|
-72.00M
-129.15M – -14.85M
-84.1% YoY
|
-43.00M
-55.88M – -30.12M
+40.3% YoY
|
| EBIT |
-31.77M
est: -2.34M (-1,257.5%)
|
-35.32M
est: -5.52M (-539.8%)
|
-70.26M
est: -18.64M (-276.9%)
|
-37.99M
est: -22.00M (-72.7%)
|
-53.21M
est: -6.18M (-761.7%)
|
-39.10M
-50.81M – -27.39M
-533.2% YoY
|
-72.00M
-129.15M – -14.85M
-84.1% YoY
|
-43.00M
-55.88M – -30.12M
+40.3% YoY
|
| Net Income |
-32.57M
est: -34.01M (+4.2%)
|
-35.89M
est: -42.40M (+15.3%)
|
-70.58M
|
-38.43M
est: 8.59M (-547.2%)
|
-42.00M
est: -42.65M (+1.5%)
|
20.00M
-149.36M – 111.84M
+146.9% YoY
|
-1.50M
-628.76M – 684.18M
-107.5% YoY
|
-65.11M
-90.47M – -39.75M
-4,240.8% YoY
|
| SGA |
19.55M
est: 8.40M (+132.8%)
|
19.56M
est: 19.80M (-1.2%)
|
22.18M
est: 44.15M (-49.8%)
|
16.52M
est: 52.11M (-68.3%)
|
9.69M
est: 14.63M (-33.7%)
|
92.61M
64.86M – 120.36M
+533.2% YoY
|
170.54M
35.16M – 305.91M
+84.1% YoY
|
101.85M
71.33M – 132.36M
-40.3% YoY
|
| EPS |
-7.89
est: -7.30 (-8.1%)
|
-8.61
est: -9.10 (+5.4%)
|
-15.19
|
-8.25
est: 1.56 (-629.7%)
|
-7.61
est: -8.35 (+8.9%)
|
-3.40
-27.07 – 20.27
+59.3% YoY
|
5.02
-113.95 – 123.99
+247.7% YoY
|
-11.80
-16.40 – -7.20
-335.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 2.1K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Adam Lukojc | CFO & Member of the Management Board | — | male |
| Adam Ostrowski | Chief Medical Officer | — | — |
| Andrew Saunders FFPM | Chief Medical Officer | — | — |
| Anna Pawluk | COO & Member of the Management Board | — | female |
| Anthony Rowen-Brown | Chief Business Officer | — | male |
| Marta Tomaszewska | Vice President of People & Culture | — | female |
| Michal Walczak | CEO, President of Management Board & Chief Scientific Officer | — | male |
| Sylvain Cottens | Co-Founder & Senior Vice President of Chemistry | — | male |
| Thomas Shepherd | Senior Vice President of Strategy | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CTX.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
